Association of the macrophage migration inhibitory factor gene -173G/C polymorphism with inflammatory bowel disease: A meta-analysis of 4296 subjects

Gene

Volumn 526, Issue 2, 2013, Pages 228-231

  Zhang, Hui ^a   Ma, Li ^b   Dong, Lian qiang ^a   Shu, Cheng ^a   Xu, Jia long ^a  

^a AIR FORCE GENERAL HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Inflammatory bowel disease; Macrophage migration inhibitory factor; Meta analysis; Polymorphism

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR;

ARTICLE; ENTERITIS; GENETIC POLYMORPHISM; HUMAN; PRIORITY JOURNAL; PUBLISHING; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

CD; CI; CONFIDENCE INTERVAL; CROHN'S DISEASE; HARDY-WEINBERG EQUILIBRIUM; HWE; IBD; INFLAMMATORY BOWEL DISEASE; MACROPHAGE MIGRATION INHIBITORY FACTOR; META-ANALYSIS; MIF; NEWCASTLE-OTTAWA SCALE; NOS; ODDS RATIO; OR; POLYMORPHISM; PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES; PRISMA; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; UC; ULCERATIVE COLITIS;

ALLELES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; ODDS RATIO; POLYMORPHISM, GENETIC; PUBLICATION BIAS;

EID: 84880752735     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.05.012     Document Type: Article

References (20)

1. Berkey C.S., Hoaglin D.C., Mosteller F., Colditz G.A. A random-effects regression model for meta-analysis. Stat. Med. 1995, 14:395-411.
2. Dambacher J., et al. Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. Inflamm. Bowel Dis. 2007, 13:71-82.
3. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
4. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
5. Fei B.Y., Lv H.X., Yang J.M., Ye Z.Y. Association of MIF-173 gene polymorphism with inflammatory bowel disease in Chinese Han population. Cytokine 2008, 41:44-47.
6. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
7. Hoi A.Y., Iskander M.N., Morand E.F. Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. Inflamm. Allergy Drug Targets 2007, 6:183-190.
8. Lees C.W., Satsangi J. Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert. Rev. Gastroenterol. Hepatol. 2009, 3:513-534.
9. Maaser C., Eckmann L., Paesold G., Kim H.S., Kagnoff M.F. Ubiquitous production of macrophage migration inhibitory factor by human gastric and intestinal epithelium. Gastroenterology 2002, 122:667-680.
10. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22:719-748.
11. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009, 151:264-269. PRISMA Group.
12. Molodecky N.A., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54.
13. Nohara H., et al. Association of the -173G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J. Gastroenterol. 2004, 39:242-246.
14. Oliver J., et al. Association of the macrophage migration inhibitory factor gene polymorphisms with inflammatory bowel disease. Gut 2007, 56:150-151.
15. Przybyłowska K., et al. Contribution of the -173G/C polymorphism of macrophage migration inhibitory factor gene to the risk of inflammatory bowel diseases. Pol. Przegl. Chir. 2011, 83:76-80.
16. Shiroeda H., et al. Association between functional promoter polymorphisms of macrophage migration inhibitory factor (MIF) gene and ulcerative colitis in Japan. Cytokine 2010, 51:173-177.
17. Sivaram G., et al. Macrophage migration inhibitory factor, Toll-like receptor 4, and CD14 polymorphisms with altered expression levels in patients with ulcerative colitis. Hum. Immunol. 2012, 73:201-205.
18. Torres M.I., Rios A. Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J. Gastroenterol. 2008, 14:1972-1980.
19. Wells G., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2011, Ottawa Health Research Institute, (www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed Oct 20, 2011).
20. Zintzaras E., Lau J. Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J. Clin. Epidemiol. 2008, 61:634-645.